Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMYMP) EBT Margin (2016 - 2025)

Historic EBT Margin for Bristol Myers Squibb (BMYMP) over the last 17 years, with Q4 2025 value amounting to 11.76%.

  • Bristol Myers Squibb's EBT Margin rose 103400.0% to 11.76% in Q4 2025 from the same period last year, while for Dec 2025 it was 19.36%, marking a year-over-year increase of 367000.0%. This contributed to the annual value of 19.36% for FY2025, which is 367000.0% up from last year.
  • Per Bristol Myers Squibb's latest filing, its EBT Margin stood at 11.76% for Q4 2025, which was up 103400.0% from 25.48% recorded in Q3 2025.
  • Over the past 5 years, Bristol Myers Squibb's EBT Margin peaked at 26.52% during Q1 2025, and registered a low of 97.06% during Q1 2024.
  • For the 5-year period, Bristol Myers Squibb's EBT Margin averaged around 10.97%, with its median value being 15.9% (2021).
  • Its EBT Margin has fluctuated over the past 5 years, first crashed by -1214900bps in 2024, then skyrocketed by 1235800bps in 2025.
  • Quarter analysis of 5 years shows Bristol Myers Squibb's EBT Margin stood at 15.5% in 2021, then increased by 5bps to 16.3% in 2022, then decreased by -11bps to 14.59% in 2023, then plummeted by -90bps to 1.42% in 2024, then skyrocketed by 729bps to 11.76% in 2025.
  • Its last three reported values are 11.76% in Q4 2025, 25.48% for Q3 2025, and 14.45% during Q2 2025.